- Home
- GAMB vs GLUE Comparison
GAMB vs GLUE Comparison
Compare GAMB & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAMB
- GLUE
- Stock Information
- Founded
- GAMB 2006
- GLUE 2019
- Country
- GAMB Jersey
- GLUE United States
- Employees
- GAMB N/A
- GLUE N/A
- Industry
- GAMB Services-Misc. Amusement & Recreation
- GLUE Biotechnology: Pharmaceutical Preparations
- Sector
- GAMB Consumer Discretionary
- GLUE Health Care
- Exchange
- GAMB Nasdaq
- GLUE Nasdaq
- Market Cap
- GAMB 338.0M
- GLUE 356.3M
- IPO Year
- GAMB 2021
- GLUE 2021
- Fundamental
- Price
- GAMB $14.08
- GLUE $5.66
- Analyst Decision
- GAMB Strong Buy
- GLUE Buy
- Analyst Count
- GAMB 7
- GLUE 3
- Target Price
- GAMB $16.00
- GLUE $12.67
- AVG Volume (30 Days)
- GAMB 235.5K
- GLUE 1.2M
- Earning Date
- GAMB 11-14-2024
- GLUE 03-13-2025
- Dividend Yield
- GAMB N/A
- GLUE N/A
- EPS Growth
- GAMB 306.73
- GLUE N/A
- EPS
- GAMB 0.78
- GLUE N/A
- Revenue
- GAMB $124,404,000.00
- GLUE $14,975,000.00
- Revenue This Year
- GAMB $18.54
- GLUE N/A
- Revenue Next Year
- GAMB $29.49
- GLUE N/A
- P/E Ratio
- GAMB $18.15
- GLUE N/A
- Revenue Growth
- GAMB 27.63
- GLUE N/A
- 52 Week Low
- GAMB $7.52
- GLUE $3.21
- 52 Week High
- GAMB $16.09
- GLUE $12.40
- Technical
- Relative Strength Index (RSI)
- GAMB 52.59
- GLUE 35.37
- Support Level
- GAMB $13.25
- GLUE $5.51
- Resistance Level
- GAMB $14.17
- GLUE $6.38
- Average True Range (ATR)
- GAMB 0.58
- GLUE 0.49
- MACD
- GAMB -0.13
- GLUE -0.07
- Stochastic Oscillator
- GAMB 49.70
- GLUE 13.22
About GAMB Gambling.com Group Limited
Gambling.com Group Ltd is a multi-award-winning performance marketing company and a provider of digital marketing services in the online gambling industry. Its principal focus is on online casino and online sports betting and the fantasy sports industry. It generates revenue by referring online gamblers to online gambling operators.
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their most advanced product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.